Universal Ibogaine advises of appointment of two new Board Members — TradingView News

Posted by:


(TheNewswire)

Calgary, AB – September 3, 2025 – TheNewswire – Universal Ibogaine Inc.(TSXV:IBO) (“UI” or the “Company”), a life sciences company with amission to research and deliver medicalized ibogaine-centeredaddiction care, advises that the existing Board of Directors of theCompany (the “Board”) appointed two new Directors to jointhe Board, effective August 28, 2025, with one of the Board membersfilling a vacant Board position which previously arose in July2025.

The two new Board members are Nia Killebrew and TonyWagner, who have joined the current Board members Nick Karos (CEO),James Duncan, and Dean Koumontzis.  Bio information for Ms. Killebrewand Mr. Wagner are contained in UI’s Management Information Circulardated July 23, 2025 (the “Circular”), which has been provided by UI inconnection with the upcoming Annual Meeting of Shareholders (the“AGM”) which is to occur on September 4, 2025.  Mr. Koumontzisis not standing for re-election to the Board at the AGM.

A copy of the Circular is available for review onSEDAR+ and on the Company’s website.

About UniversalIbogaine Inc. 

UI is a life sciences company,with a mission totransform addiction treatment using medicalized ibogaine through aplanned Canadian clinical trial focused on opioid use disorder, andultimately to utilize that treatment protocol globally through plannedfuture licensing agreements.  UI is concurrently developing a state of the art holisticaddiction treatment protocol at its Kelburn Recovery Centre (locatednear Winnipeg, Manitoba) that, which when paired with the plannedibogaine detox protocol, is intended to revolutionize the way we treataddiction and drastically improve the lives of individuals andfamilies affected by addiction.  

NEITHER THE TSXVENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM ISDEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTSRESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THISRELEASE.

CAUTIONARY STATEMENTREGARDING FORWARD-LOOKING STATEMENTS  

‎This news release may containforward-looking statements and information. Forward-lookinginformation is frequently characterized by words such ‎as”plans”, “planned”, “expect”,”project”, “intends”, “intended””will”, “believe”, “anticipate”,”estimate”, “scheduled”,‎‎”potential”, or other similar words, or statementsthat certain events or conditions “may”, “should”or ‎‎”could” occur.  The forward-looking statements andinformation are based on certain key expectations ‎and assumptionsmade by UI at the date the statements are made.  Although UI believesthat the expectations and assumptions on which the forward-‎lookingstatements are based are reasonable, undue reliance should not beplaced on the forward-‎looking statements because UI can give noassurance that they will prove to be correct. 

Since ‎forward-looking statementsaddress future events and conditions, by their very nature theyinvolve ‎inherent risks and uncertainties. Actual results coulddiffer materially from those currently anticipated ‎due to a numberof factors and risks, which include, but are not limited to, risksthat required ‎regulatory approvals are not obtained. The reader iscautioned that assumptions used in the ‎preparation of suchinformation, although considered reasonable by UI at the time of‎preparation, may prove to be incorrect and readers are cautionednot to place undue reliance on ‎forward-looking information, whichspeaks only to conditions as of the date hereof.  UI does not‎undertake any obligation to release publicly any revisions toforward-looking information contained ‎herein to reflect events orcircumstances that occur after the date hereof or to reflect theoccurrence ‎of unanticipated events, except as may be required underapplicable securities laws. ‎ 

Additional information identifying risks anduncertainties that could affect financial results and the Company iscontained in the Company’s filings with Canadian securitiesregulators, which are available at www.sedar.com

For furtherinformation:  

Nick Karos, CEO

Universal Ibogaine Inc.

612-309-3527

Nick.Karos@universalibogaine.com

Related Links 

https://universalibogaine.com  

Copyright (c) 2025 TheNewswire – All rights reserved.



Source link

0
UA-77446339-1